Use of this database indicates the user is an Eye Care/Health Care Professional and has read, understands and accepted all the terms of use as outlined in the Disclaimer.

The recent crisis has brought into sharp focus (excuse the pun) the inadequacy of the current optical business model, i.e. No patients = No revenue. But that’s the same for the all bricks and mortar retail during lockdown, I hear you all cry. That is, of course, true for most retailers, and it’s certainly true for the optical businesses that are heavily focussed on spectacles to generate their revenue. Read the full article and post your thoughts/comments/questions in The Forum!



“An easy, accessible & reliable virtual solution for your next event.”

As an approved GOC continuing education provider, we are best known for our provision of online eyecare continuing education. Now, Webineyes Virtual Production Services utilizes this expertise & experience to support companies & associations to convert their existing & future events to webinars or virtual meetings.



The Consulting Rooms, 38 Harborne Road, Edgbaston, Birmingham, B15 3EB

Mr Imran Masood is a Consultant Ophthalmic Surgeon and Director of the Glaucoma service at the prestigious Birmingham and Midland Eye Centre (a tertiary referral centre). He has subspecialist interests in the assessment, diagnosis and medical and surgical management of all forms of Glaucoma.

Following a recent conference where the subject of punctal occlusion treatment (POT) came up on more than one occasion it was felt worthwhile to look again at a 2017 clinical trial investigating the effect of such a treatment on contact lens discomfort. These results indicated that POT can produce statistically significant improvements in the frequency, severity, and overall sum of subjective symptoms associated with dryness among SCL wearers, while the categorical InflammaDry (ID) test showed improvement although no statistically significant change was found. These results indicate that POT is a promising option for SCL wearers who have dryness complaints.

I would encourage you to look especially at the CLDEQ-8 results and Additional Analysis. It is important to note that all subjects were only included for POT after establishing there was no active ocular surface inflammation by the ID test at the point of treatment, not the same date as baseline. The trial was jointly funded by a grant from Positive Impact and Beaver Visitec International. Further product information can be obtained from Positive Impact by email This email address is being protected from spambots. You need JavaScript enabled to view it. Discussion on the clinical trial welcomed to This email address is being protected from spambots. You need JavaScript enabled to view it.

Professional organisations have as an ethos, dedication to the advancement of the knowledge and practice of professions through developing, supporting, regulating and promoting professional standards for technical and ethical competence.

In this they are all concerned with the public benefit as well as the reputation of professionals. They aim to maintain and develop professionalism and thereby securing high quality professional services for society.

In line with that general statement of the nature of professional organisations the ABDO’s specific objectives are:

‘To support, protect and advance the character, status and interests of dispensing opticians’.

‘The advancement, for the benefit of the public, of the science and art of dispensing optics and promotion of research into such science and art, provided that the useful results of any such research is disseminated for public benefit’

Within the structure of the ABDO exists the facility to encourage and develop their member’s ideas on possible research subjects that fulfil those criteria. The Education Trust encourages and promotes education and research in the art and science of dispensing optics for the public benefit. An excellent article on the subject appeared in issue 34 of Re:View. If you don't have it email me This email address is being protected from spambots. You need JavaScript enabled to view it. I will send it to you. For an initial informal exploration of your ideas contact Alexandra Webster BMus, MSc, PGDipE, FBDO CL, FHEA by email: This email address is being protected from spambots. You need JavaScript enabled to view it.

An example of a small-scale in-practice clinical trial, the results of which were first published in clinical trials poster form (click Read more to see full poster) on the ABDO stand at Optrafair in 2018, was the ABDO Contact Lens Uncorrected Cylinder (CLUC) Trial comparing low-cyl toric contact lenses to spherical lenses. The results of which not only proved very interesting but had direct implications in practice.

This is but an example, your idea for consideration could be related to any aspect of practice in the role of DO or CLO that could fulfil the ABDO’s objectives.

Kathryn Albany-Ward, Founder of Colour Blind Awareness

You might be surprised to learn that colour blindness can be considered both a disability and a Special Educational Need but despite this it is an under-recognised and poorly understood condition.

Let’s start by being honest. Do you screen children for CVD on first visit as a matter of course? If you do screen, once you’ve given a patient a diagnosis of colour blindness, how often do you think about the impact this will really have on their everyday life? Do you think it’s condition which isn’t really that important?

Have you ever wondered how the street outside your premises might appear or the immediate challenges they might face just to get home? If they are a child, how might they see their classroom? How might their confidence and even their mental health be affected?

Myopia control isn’t rocket science; every OD who reads this has the clinical skills and education to not only correct myopia but to apply the latest science to help patients manage progression of myopia. Care of myopic patients is Optometry’s core competence and as the standards change from just being able to correct myopia to being able to influence the progression it’s vital we own the methods behind myopia control, practice them and educate our patients on our abilities to do so. Arguably managing myopia is quickly becoming the standard of care; not just correcting it through standard methods.

sensus-logoWe find ourselves in a turbulent, challenging but exciting time for the Medical Device and In Vitro Diagnostics Industries in The UK and Europe. In this article we will highlight the current status of regulation in Europe and consider how this, and Brexit will impact the way we do business going forwards.